Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. A position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation

Anne B Chang, Scott C Bell, Cass A Byrnes, Keith Grimwood, Peter W Holmes, Paul T King, John Kolbe, Louis I Landau, Graeme P Maguire, Malcolm I McDonald, David W Reid, Francis C Thien and Paul J Torzillo
Med J Aust 2010; 193 (6): 356-365. || doi: 10.5694/j.1326-5377.2010.tb03949.x
Published online: 20 September 2010


  • Consensus recommendations for managing chronic suppurative lung disease (CSLD) and bronchiectasis, based on systematic reviews, were developed for Australian and New Zealand children and adults during a multidisciplinary workshop.

  • The diagnosis of bronchiectasis requires a high-resolution computed tomography scan of the chest. People with symptoms of bronchiectasis, but non-diagnostic scans, have CSLD, which may progress to radiological bronchiectasis.

  • CSLD/bronchiectasis is suspected when chronic wet cough persists beyond 8 weeks. Initial assessment requires specialist expertise. Specialist referral is also required for children who have either two or more episodes of chronic (> 4 weeks) wet cough per year that respond to antibiotics, or chest radiographic abnormalities persisting for at least 6 weeks after appropriate therapy.

  • Intensive treatment seeks to improve symptom control, reduce frequency of acute pulmonary exacerbations, preserve lung function, and maintain a good quality of life.

  • Antibiotic selection for acute infective episodes is based on results of lower airway culture, local antibiotic susceptibility patterns, clinical severity and patient tolerance. Patients whose condition does not respond promptly or adequately to oral antibiotics are hospitalised for more intensive treatments, including intravenous antibiotics.

  • Ongoing treatment requires regular and coordinated primary health care and specialist review, including monitoring for complications and comorbidities.

  • Chest physiotherapy and regular exercise should be encouraged, nutrition optimised, environmental pollutants (including tobacco smoke) avoided, and vaccines administered according to national immunisation schedules.

  • Individualised long-term use of oral or nebulised antibiotics, corticosteroids, bronchodilators and mucoactive agents may provide a benefit, but are not recommended routinely.

Although regarded in high-income countries as an orphan disease,1,2 bronchiectasis remains a major contributor to chronic respiratory morbidity in less-affluent populations, both Indigenous3 and non-Indigenous.1,4,5 Moreover, delays in diagnosis of bronchiectasis of years to decades commonly occur in children4 and adults,6 and it is likely that many remain undiagnosed and untreated, risking premature and accelerated pulmonary decline.7,8 This position statement from the Thoracic Society of Australia and New Zealand (TSANZ) and the Australian Lung Foundation (ALF), developed at a multidisciplinary workshop, presents consensus recommendations for managing chronic suppurative lung disease (CSLD), including bronchiectasis, in children and adults in settings other than remote and rural Indigenous Australian communities; recommendations for these communities are available elsewhere.3 This statement provides an overview and is not intended to replace individualised specialist care. As with all guidelines, it does not substitute for sound clinical judgement, particularly when addressing such a phenotypically heterogeneous condition as bronchiectasis.9 The development process undertaken by the working group is outlined in Box 1 and the full position statement will be available on the TSANZ website (

Bronchiectasis and CSLD — incidence, diagnosis and mortality rates

The only available Australasian data on CSLD and bronchiectasis are in children aged under 15 years. In New Zealand, the national incidence of bronchiectasis is 3.7/100 000 per year,4 which is almost twice that of cystic fibrosis, while in Central Australian Indigenous children the estimated prevalence of bronchiectasis is at least 1470/100 000.12 Estimated bronchiectasis prevalence rates in the United States range from 4.2/100 000 in 18–34-year-olds to 272/100 000 in those over 75 years.13 Patients with bronchiectasis were found to spend two more days in hospital and have higher annual medical care expenditure (by US$5681) than age- and sex-matched controls with other chronic illnesses, such as diabetes and heart failure.13

Bronchiectasis can be misdiagnosed as, or coexist with, other chronic respiratory diseases. Between 29% and 50% of people with chronic obstructive pulmonary disease (COPD) have bronchiectasis,3 as do as many as 40% of newly referred patients with difficult-to-control asthma and a chronic cough;14 thus it is likely that many people with chronic respiratory symptoms due to CSLD or bronchiectasis remain undiagnosed.

Bronchiectasis causes premature death.15 The only published Australian mortality data for bronchiectasis are from a hospital-based cohort of 61 adults (mean [SD] age, 42 [15] years) in Central Australia where 11.5% died within 12 months.15 In other countries, mortality rates in adults with bronchiectasis vary widely, from 58% survival at 4 years (Turkey) and 75% survival at 8.8 years (Finland) to 81% survival at 14 years (Scotland).16 Complications and comorbidities associated with bronchiectasis extend beyond the respiratory system and include cardiac and psychological effects.17

Definitions and their limitations

The definitions of bronchiectasis, CSLD and protracted bacterial bronchitis are compromised by overlapping symptoms and signs that are not specific to an individual condition (Box 2). Thus, some clinicians, particularly paediatricians, use the term CSLD for all three conditions. Whether these three conditions are different, or are part of a spectrum of disease severity, remains undetermined.18 While the principles of managing all three conditions are similar, there are few published intervention studies, especially for managing patients with CSLD. Consequently, many of the recommendations for CSLD are extrapolated from studies of bronchiectasis. Until further evidence is available, we believe including CSLD is important given (i) the spectrum of disease; (ii) the increasing evidence that early diagnosis and treatment improves outcomes and reduces pulmonary decline;8,26,27 and (iii) the difficulties of providing robust definitions.

Aetiology and investigations of a patient with CSLD/bronchiectasis

Plain chest radiographs are insensitive, and c-HRCT (conventional or multidetector) scans, despite their limitations (Box 2), remain the diagnostic gold standard. As children, adolescents and young adults are at greater risk from radiation-induced cancers later in life,24 the c-HRCT protocol must ensure the lowest possible radiation exposure to obtain adequate assessment.28

Aetiological associations

Several causative and associated factors are described for CSLD/bronchiectasis (Box 3). Identifying aetiology and disease severity can influence management, including treatment intensity.29,30 Investigations for specific causes of CSLD/bronchiectasis are recommended (Box 4), even though many patients will not have an identifiable aetiology.3,4,9

Assessment of severity

In addition to routine clinical data (cough, sputum, exacerbation rate, wellbeing, etc) and radiological assessment, objective tests provide information about disease severity and prognosis.

Lung function

Bronchiectasis is primarily an airway disease and, although spirometry data are classically obstructive, a restrictive pattern is also recognised.5 Spirometry and lung-volume measurements should be performed at diagnosis, and spirometry repeated at each review, even though these tests can be relatively insensitive in mild disease and in children.12 Many patients have a gradual deterioration in lung function over time.5,7 If serial pulmonary function tests indicate disease progression, a step-up in therapy is usually required. Studies in children show that spirometric volumes can stabilise and even improve.8,26,27 In adults with moderate-to-severe bronchiectasis, mortality risk is associated with the degree of lung-function impairment.16 Other tests, including complex pulmonary-function tests and the 6-minute walk test, are sometimes used for determining functional impairment, but these are not discussed further.


Surveillance of airway or sputum microbiology helps guide antibiotic therapy in CSLD/bronchiectasis,31 especially if there is deterioration or inadequate response to current treatment. The most common pathogens recovered from children are non-typeable Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis.4,32 In adults, Pseudomonas aeruginosa and non-typeable H. influenzae predominate.33 About 25%–45% of airway samples fail to grow pathogenic bacteria. As disease progresses, the microbiological flora changes, often with P. aeruginosa appearing in more advanced disease and predicting a worse prognosis.33 Aspergillus and non-tuberculous mycobacteria species are detected in some adults with bronchiectasis, although their pathogenic role is often uncertain.33 Nonetheless, non-tuberculous mycobacteria have been implicated in exacerbations31 and pulmonary deterioration.34

Other tests

Pulmonary arterial hypertension complicates severe CSLD/bronchiectasis.12 In advanced disease, chronic or nocturnal hypoxaemia is common, and selected patients require arterial blood gas, an echocardiogram and an overnight oxygen assessment.

Management (Box 5)

Early and effective management reduces short- and long-term morbidity.8,26,27,40 In primary ciliary dyskinesia, adults diagnosed late have significantly poorer lung function.41 With appropriate treatment, lung disease complicating primary immunodeficiency should not deteriorate.8,27 In a Melbourne cohort, longer duration of chronic productive cough was related to reduced lung function.9 At the initial referral, the mean percentage predicted, forced expiratory volume in 1 second (FEV1) in those in the cohort with chronic cough from childhood was 18% lower than those with adult-onset symptoms.9


CSLD/bronchiectasis arises from infection and an ineffective host immune response involving uncontrolled recruitment and activation of inflammatory cells within the lower airways.42 The subsequent release of mediators, such as proteases and free radicals, causes bronchial-wall injury and dilatation.42 Consequently, intensive antibiotic treatments are advocated to reduce the microbial load. For acute exacerbations, depending on the severity of the episode, oral antibiotics and ambulatory care are usually tried first.19 More severe exacerbations require hospitalisation with intravenous antibiotics combined with intensified physiotherapy and other airway clearance methods, including nebulised therapy.19,40

Response to therapy includes reduction in sputum volume and purulence, improvement in cough characteristics (wet to dry or cessation of cough), general wellbeing, QoL and markers of systemic inflammation (C-reactive protein), demonstration of microbial clearance, and “return to baseline” state.19,40

Prolonged oral or inhaled antibiotic treatments are sometimes used to improve QoL and to prevent exacerbations, although the evidence is limited and the possibility of developing antibiotic resistance is of concern. There is increasing interest in macrolides for this purpose; however, further studies are required to establish their role in CSLD/bronchiectasis. Additionally, before using macrolides long-term, the presence of non-tuberculous mycobacteria should be excluded in adults and in older children capable of providing sputum samples.43

Recommendation 6

Antibiotic selection (Box 6) is based on lower airway culture results (sputum or bronchoscopy washings) when available, local antibiotic susceptibility patterns, clinical severity and patient tolerance, including allergy.

Grade: strong; evidence: moderate

Bronchodilators and corticosteroids

Patients with CSLD/bronchiectasis may have coexistent asthma with wheeze and/or dyspnoea that is responsive to β2-agonist medications. Reports on asthma symptoms in those with CSLD/bronchiectasis vary from 11% to 46%.2,44 While, in some studies, bronchiectasis is ascribed to asthma, it is more likely in such cases that asthma was initially misdiagnosed or coexisted with CSLD/bronchiectasis.18,20 When present, asthma therapies should be used in accordance with asthma guidelines.

Inhaled corticosteroids provide, at best, a modest benefit in CSLD/bronchiectasis, including in patients with P. aeruginosa infection.38 A Cochrane review found no significant differences between patients receiving very high inhaled corticosteroid doses (2 g/day) and placebo controls.38

Chest physiotherapy, airway clearance methods, exercise and pulmonary rehabilitation

Despite lacking a robust evidence base, chest physiotherapy to improve airway secretion clearance is standard treatment in children36 and adults37,46 with CSLD/bronchiectasis. Nevertheless, available studies suggest chest physiotherapy is beneficial, with improved QoL and exercise capacity and reduced cough and sputum volumes.37,46 Given the various techniques in airway clearance and the increased efficacy when therapy is individualised,36 specific chest physiotherapy expertise should be sought.

Pulmonary rehabilitation is employed in several different chronic respiratory conditions. It involves a multidisciplinary approach, including exercise training, self-management education, and psychosocial and nutritional intervention.47 Inspiratory muscle training may be beneficial in adults with bronchiectasis. A recent small RCT showed that an 8-week program of pulmonary rehabilitation and inspiratory muscle training significantly improved the incremental shuttle walking test.48 Unless specific contraindications exist, physical activity should be encouraged.


Poor nutrition (both macro- and micronutrition) compromises innate and adaptive immunity. Studies in other chronic respiratory diseases49 indicate that poor nutrition may be a risk factor for respiratory exacerbations in CSLD/bronchiectasis.

Recommendation 21

Regularly monitor and manage complications and comorbidities (Box 7). When present, these are managed according to standard guidelines.

Grade: strong; evidence: moderate

Other treatments

Various other treatments are available, but with little supportive data (Box 5). Current management strategies have reduced the need for surgical interventions, which carry a small but significant risk of morbidity and mortality. Lung transplantation should be considered in those with end-stage lung disease.

Public health issues, prevention and appropriate health care delivery

The socioeconomic determinants of health, including their impact on prevalence and disease progression of CSLD/bronchiectasis, cannot be adequately addressed here. Immunisations that prevent acute respiratory infections are recommended despite the lack of specific evidence in relation to bronchiectasis. For pneumococcal immunisation, limited evidence supports using the 23-valent pneumococcal polysaccharide vaccine for reducing acute infective exacerbations.39

Delivery of chronic disease programs requires comprehensive and highly skilled primary health care services. Education of primary health care providers should focus on identifying children and adults for appropriate referral and high-quality local management. Initial assessment requires specialist expertise. Like other chronic illnesses, individualised and multidisciplinary case management operating within an interprofessional framework is optimal.50 Similarly, clinical deterioration should prompt early referral for specialist care. Those with moderate or severe disease are best managed by a multidisciplinary approach to chronic care.

1 Development process of the position statement

GRADE approach to guideline development

The recommendations were based on the available evidence (Box 5). Principles of evidence-based medicine and the revised GRADE10 approach to guideline development were used to categorise recommendations into: strong, weak, or no specific recommendation.10

The implications of a strong recommendation are:10

  • For patients — most people in your situation would want the recommended course of action and only a small proportion would not; request discussion if the intervention is not offered.

  • For clinicians — most patients should receive the recommended course of action.

  • For policymakers — the recommendation can be adopted as a policy in most situations.

The implications of a weak recommendation are:

  • For patients — most people in your situation would want the recommended course of action, but many would not.

  • For clinicians — you should recognise that different choices will be appropriate for different patients and that you must help each patient to arrive at a management decision consistent with her or his values and preferences.

  • For policymakers — policy making will require substantial debate.

The levels of evidence provided by GRADE are:

High = Further research is very unlikely to change our confidence in the estimate of effect.

Moderate = Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low = Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low = Any estimate of effect is very uncertain.

When relative risk was not available in publications, the decision to upgrade the evidence was based primarily on the likelihood of further research having an effect on the recommendation.

Database search

An updated search (from a previous search in October 20073) was conducted in July 2009 by one of us (A B C) using the text words “bronchiectasis” or “suppurative lung disease” and “controlled trials” in the PubMed and Cochrane Central Library databases. Only full articles published in English were retrieved. A draft of this document was circulated to all authors before a workshop held in Brisbane on 7 August 2009.

Consensus process

Recommendations were drafted and finalised by complete agreement by the eight authors who attended the workshop. The assigned evidence level (defined above) of recommendations was also obtained (complete agreement by the workshop attendees). This document and a summary table were then circulated to the entire group of 13 authors for assessment using the GRADE descriptors.10 Strength of recommendations were assigned by formal voting rules,11 and agreement with a statement by more than 75% of the group was defined a priori as consensus.

GRADE = Grading of Recommendations Assessment, Development and Evaluation

2 Definitions


Bronchiectasis is a radiological or pathological diagnosis characterised by abnormal irreversible bronchial dilatation. It is mostly diagnosed by a chest high-resolution computed tomography (c-HRCT) scan, which is the current diagnostic gold standard. However, a radiological diagnosis of bronchiectasis may be reported by radiologists in patients with interstitial lung diseases (eg, pulmonary fibrosis) where traction on the airways causes bronchial dilatation. Traction bronchiectasis in the absence of a chronic productive cough will not be considered further in this position statement.

In adults, the dominant presenting symptom is a chronic or recurrent productive cough. In children, the cough is wet rather than productive, as young children do not usually expectorate,18 and after treatment the cough often temporarily resolves.19

Chronic suppurative lung disease (CSLD)

CSLD describes a clinical syndrome in which there are symptoms indicating chronic endobronchial suppuration (see Recommendation 1a, page 357) with or without evidence of radiological bronchiectasis on c-HRCT scans. However, absence of symptoms (other than wet cough) and signs does not reliably exclude either bronchiectasis or CSLD. Lung abscess and empyema (previously considered as within the CSLD spectrum) have distinct radiological characteristics and are not discussed here.

Chronic infective bronchitis and protracted bacterial bronchitis

Most patients have a productive or wet cough for several years before a diagnosis is made.5,12 Pathobiological studies and clinical observations suggest many patients have bronchitis initially that, if left untreated, gradually evolves into bronchiectasis.18 The entity of protracted bacterial bronchitis has been used in relation to children in whom a prolonged wet cough completely resolves after antibiotic treatment.18 Many of these children were previously misdiagnosed with asthma and had responded poorly to asthma therapies. In some settings these children would have been classified as having “difficult or severe asthma”.18,20 We also suspect that a proportion of adults diagnosed with “difficult” and/or neutrophilic asthma in fact have bronchiectasis as their primary diagnosis. In a recent study, 40% of newly referred adults with “difficult asthma” were found to have bronchiectasis.14 While the evidence is limited, it is highly likely that, in some circumstances, untreated bronchitis progresses to bronchiectasis and/or airflow limitation.18 The definitions of bronchiectasis, CSLD and protracted bacterial bronchitis have limitations, as their associated symptoms and signs overlap and lack specificity. However, absolute reliance on a radiology-based definition is also unsatisfactory for the following reasons:
1. It is not known when diagnostic radiological changes of bronchiectasis appear in the course of the illness in patients with symptoms of CSLD/bronchiectasis. Studies in adults found that bronchography (the old diagnostic gold standard) is superior to a c-HRCT scan at detecting bronchiectasis, especially when mild disease is present.21 Another study reported that by using a 16-slice computed tomography scan of the chest (contiguous 1-mm slices), 40 extra lobes with evidence of bronchiectasis were identified in 53 adults previously examined by conventional c-HRCT scans.22
2. One of the key signs of bronchiectasis on c-HRCT scans, increased bronchoarterial ratio, is significantly influenced by age.23 However, it remains to be determined whether a lower bronchoarterial ratio should be used in children.
3. At least two c-HRCT scans are required to fulfil the criteria of “irreversible dilatation”. Nonetheless, performing more than one c-HRCT scan purely for diagnostic, as opposed to management, reasons is controversial because of the small, but increased, radiation-induced cancer risk24 and, moreover, is often impractical in some settings.
4. c-HRCT scans performed during various clinical states, such as during an acute respiratory illness, immediately after treatment and when clinically stable, can yield different results.3,25

5 Possible interventions and the evidence base for management of chronic suppurative lung disease and bronchiectasis

Evidence type/study

Summary of results


Antibiotics (by type)


Cochrane review, other systematic review*

Generally beneficial. See section on Antibiotics (page 359)

Antibiotic resistance


RCTs and review for 2–6 months*

Exacerbations significantly reduced in treatment arm; sputum volume and symptoms reduced; some patients showed improvement in pulmonary function tests*

Concerns over antibiotic resistance

Nebulised tobramycin

Double-blind crossover RCT in 30 patients with PsA, 6 months in each arm*

Fewer admissions and days in hospital in tobramycin arm

Antibiotic resistance; nebulised tobramycin poorly tolerated by some patients*

Antibiotics (by duration)

Short term (< 1 month)

Several cohort studies*

General clinical improvement

Medium term (1–11 months)

Cochrane review, other systematic reviews*

Improvement with amoxycillin and macrolides (see above). Adults with PsA had shorter hospitalisations, but no change in QoL*

Long term (≥ 12 months)


Adults with PsA had fewer admissions and days in hospital.* Reduced general disability in those taking tetracycline compared with placebo*



Cochrane review*


Cohort study of indomethacin (25 mg three times a day for 28 days) reduced neutrophil chemotaxis, but no change in sputum albumin, elastase or myeloperoxidase levels*

Inhaled indomethacin

Cochrane review35

RCT in 25 adults, some with CSLD. Reduced sputum volume and improved dyspnoea score



Cochrane review*

Studies only in acute phase

Not universally available

Recombinant human deoxyribonuclease

Systematic review*

Increased exacerbation rate and accelerated decline in FEV1

Airway clearance

Chest physiotherapy

Cochrane review* and RCTs36,37

Two small trials in patients with bronchiectasis. Recent RCT37 showed benefit for cough and subjective scores, exercise capacity and 24-hour sputum volume. A study in children showed improvement in sputum volume and FEV136

Inhaled hyperosmolar agents

Cochrane review, additional RCT (non-blinded) using 7% hypertonic saline*

Two small short-term studies of mannitol showed benefit in QoL only

Asthma therapies

Inhaled corticosteroids

Cochrane review38

No difference in any outcome when only RCTs of inhaled corticosteroids v placebo were included. Reduced exacerbation rate in adults with PsA

Limited applicability in children, as high doses are used and children are less likely to have PsA

Oral corticosteroids

Cochrane review*


No data*


Cochrane review*


No data*

β2 Agonist

Cochrane review*


No data*

Leukotriene receptor antagonist

Cochrane review*


No data*

Physical training

Cochrane review and RCT, which was included in Cochrane review as an abstract (data changed)*

Pulmonary rehabilitation improves exercise tolerance, no additional advantage of simultaneous inspiratory muscle training

Oxygen (domiciliary)

No data as sole therapy*

Consider data from patients with COPD showing benefit in survival*


Cochrane review*

No RCTs. Cohort studies suggest a benefit in selected cases*

Reduction in exacerbation rate similar in medically treated group.* Adverse events of surgery*


Pneumococcal conjugate and polysaccharide vaccines

Cochrane review39

Single RCT in adults that was inclusive of COPD and other chronic lung disease

Advocated, as vaccines reduce pneumococcal infection risk and respiratory infections

Influenza vaccines

Cochrane review*


Advocated in accordance with national guidelines



Improvement in QoL but no effect on sputum volume or the 6-min walk test

Model of follow-up

Nurse led

Cochrane review*

No difference in exacerbations, but increase in hospitalisations in nurse-led care compared with doctor-led care

Increased health care cost implications

CSLD = chronic suppurative lung disease. FEV1 = forced expiratory volume in 1 second. NSAIDs = non-steroidal anti-inflammatory drugs. PsA = Pseudomonas aeruginosa. QoL = quality of life. RCT = randomised controlled trial. COPD = chronic obstructive pulmonary disease. QoL = quality of life. RCT = randomised controlled trial.

* No other data found by single-reviewer PubMed search — July 2009 (for references, see Chang AB, Grimwood K, Macguire G, et al3; and Chang AB, Redding GJ, Everard ML18).

6 Empirical antibiotic therapy and treatment for specific pathogens — chronic suppurative lung disease and bronchiectasis

Mild-to-moderate exacerbation (oral therapy)

Severe exacerbation (intravenous therapy)

Initial empirical therapy*

Amoxycillin–clavulanate or doxycycline

Children: cefuroxime, cefotaxime or ceftriaxone. Adults: ticarcillin–clavulanate or ceftazidime ± tobramycin§

Haemophilus influenzae

β-Lactamase negative



β-Lactamase positive

Amoxycillin–clavulanate or doxycycline

Cefuroxime, cefotaxime or ceftriaxone

Streptococcus pneumoniae


Benzylpenicillin G

Moraxella catarrhalis


Cefuroxime, cefotaxime or ceftriaxone

Staphylococcus aureus



Methicillin-resistant Staphylococcus aureus

Seek specialist advice

Seek specialist advice

Pseudomonas aeruginosa

Ciprofloxacin (maximum of 14 days)

Children and adults: ticarcillin–clavulanate or ceftazidime ± tobramycin§

Non-tuberculous mycobacteria

Seek specialist advice

Seek specialist advice

* In addition to clinical severity, initial empirical therapy is also guided by any previous lower-airway culture results (sputum or bronchoscopy washings), local antibiotic susceptibility patterns and prior responses to antibiotic treatments. In children too young to expectorate sputum and when no previous lower-airway culture results are available, prescribed empirical antibiotic therapy should be active against H. influenzae, S. pneumoniae and M. catarrhalis, the respiratory bacterial pathogens most commonly found in this age group. Doxycycline is used only in adults and children over 8 years of age. Available in New Zealand. § Emerging evidence in adults (but not children) indicates that treating P. aeruginosa infection with combined β-lactam and aminoglycoside antibiotic therapy provides no additional clinical benefit and is associated with more frequent adverse events than treatment with a single β-lactam agent.

  • Anne B Chang1,2
  • Scott C Bell3,4
  • Cass A Byrnes5,6
  • Keith Grimwood7,4
  • Peter W Holmes8
  • Paul T King8
  • John Kolbe9,6
  • Louis I Landau10
  • Graeme P Maguire11
  • Malcolm I McDonald12
  • David W Reid13
  • Francis C Thien14
  • Paul J Torzillo15

  • 1 Royal Children's Hospital and Queensland Children’s Medical Research Institute, Brisbane, QLD.
  • 2 Respiratory Program, Child Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT.
  • 3 The Prince Charles Hospital, Brisbane, QLD.
  • 4 School of Medicine, University of Queensland, Brisbane, QLD.
  • 5 Starship Children's Hospital, Auckland, NZ.
  • 6 University of Auckland, Auckland, NZ.
  • 7 Queensland Paediatric Infectious Disease Laboratory, Royal Children's Hospital, Brisbane, QLD.
  • 8 Monash Medical Centre, Melbourne, VIC.
  • 9 Auckland City Hospital, Auckland, NZ.
  • 10 Health Department of Western Australia, Perth, WA.
  • 11 School of Medicine and Dentistry, James Cook University, Cairns, QLD.
  • 12 Department of Health and Families, Darwin, NT.
  • 13 Royal Hobart Hospital, University of Tasmania, Hobart, TAS.
  • 14 Box Hill Hospital, Eastern Health, Monash University, Melbourne, VIC.
  • 15 Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW.



The workshop was partly funded by the Queensland Children’s Medical Research Institute and National Health and Medical Research Council (NHMRC) grants 389837 and 490321. Anne Chang is funded by an NHMRC practitioner fellowship (grant 525216) and the Royal Children’s Hospital Foundation.

Competing interests:

Anne Chang is a Chief Investigator on an NHMRC grant for evaluating azithromycin for bronchiectasis in Indigenous children. Scott Bell has received funding from Boehringer Ingelheim for planning a phase III study of tiotropium in patients with cystic fibrosis. He is a Chief Investigator on an NHMRC grant application evaluating azithromycin and hypertonic saline for adults with bronchiectasis. Cass Byrnes is a Principal Investigator on a New Zealand Health Research Council grant for evaluating azithromycin for bronchiectasis in Indigenous children. She is also the Chief Investigator on a grant for a randomised controlled intervention study of children at high risk of chronic lung disease, and is on the organising committee of the annual respiratory conference sponsored by Boehringer Ingelheim. Keith Grimwood is on the advisory board in NZ for PhiD-CV (synflorix), a pneumoccocal conjugate vaccine. Keith Grimwood and Paul Torzillo are Chief Investigators on an NHMRC grant for evaluating azithromycin for bronchiectasis in Indigenous children.

  • 1. Bilton D. Update on non-cystic fibrosis bronchiectasis. Curr Opin Pulm Med 2008; 14: 595-599.
  • 2. Santamaria F, Montella S, Pifferi M, et al. A descriptive study of non-cystic fibrosis bronchiectasis in a pediatric population from central and southern Italy. Respiration 2009; 77: 160-165.
  • 3. Chang AB, Grimwood K, Macguire G, et al. Management of bronchiectasis and chronic suppurative lung disease (CSLD) in Indigenous children and adults from rural and remote Australian communities. Med J Aust 2008; 189: 386-393. <MJA full text>
  • 4. Twiss J, Metcalfe R, Edwards E, Byrnes C. New Zealand national incidence of bronchiectasis ‘‘too high’’ for a developed country. Arch Dis Child 2005; 90: 737-740.
  • 5. King PT, Holdsworth SR, Freezer NJ, et al. Outcome in adult bronchiectasis. COPD 2005; 2: 27-34.
  • 6. King PT, Holdsworth SR, Freezer NJ, et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006; 100: 2183-2189.
  • 7. Twiss J, Stewart AW, Byrnes CA. Longitudinal pulmonary function of childhood bronchiectasis and comparison with cystic fibrosis. Thorax 2006; 61: 414-418.
  • 8. Kapur N, Masters IB, Chang AB. Longitudinal growth and lung function in pediatric non-CF bronchiectasis — what influences lung function stability? Chest 2010; 138: 158-164.
  • 9. King PT, Holdsworth SR, Farmer M, et al. Phenotypes of adult bronchiectasis: onset of productive cough in childhood and adulthood. COPD 2009; 6: 130-136.
  • 10. Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group. Going from evidence to recommendations. BMJ 2008; 336: 1049-1051.
  • 11. Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008; 337: a744.
  • 12. Chang AB, Masel JP, Boyce NC, et al. Non-CF bronchiectasis: clinical and HRCT evaluation. Pediatr Pulmonol 2003; 35: 477-483.
  • 13. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005; 12: 205-209.
  • 14. Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of high resolution computed tomography scans in severe asthma. Chest 2009; 136: 1521-1528.
  • 15. Steinfort DP, Brady S, Weisinger HS, Einsiedel L. Bronchiectasis in Central Australia: a young face to an old disease. Respir Med 2008; 102: 574-578.
  • 16. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009; 34: 843-849.
  • 17. O’Leary CJ, Wilson CB, Hansell DM, et al. Relationship between psychological well-being and lung health status in patients with bronchiectasis. Respir Med 2002; 96: 686-692.
  • 18. Chang AB, Redding GJ, Everard ML. State of the art — Chronic wet cough: protracted bronchitis, chronic suppurative lung disease and bronchiectasis. Pediatr Pulmonol 2008; 43: 519-531.
  • 19. Kapur N, Masters IB, Chang AB. Exacerbations in non-cystic fibrosis bronchiectasis: clinical features and investigations. Respir Med 2009; 103: 1681-1687.
  • 20. Donnelly D, Critchlow A, Everard ML. Outcomes in children treated for persistent bacterial bronchitis. Thorax 2007; 62: 80-84.
  • 21. Silverman PM, Godwin JD. CT/bronchographic correlations in bronchiectasis. J Comput Assist Tomogr 1987; 11: 52-56.
  • 22. Hill LE, Ritchie G, Wightman AJ, et al. Comparison between conventional interrupted high-resolution CT and volume multidetector CT acquisition in the assessment of bronchiectasis. Br J Radiol 2010; 83: 67-70.
  • 23. Matsuoka S, Uchiyama K, Shima H, et al. Bronchoarterial ratio and bronchial wall thickness on high-resolution CT in asymptomatic subjects: correlation with age and smoking. AJR Am J Roentgenol 2003; 180: 513-518.
  • 24. Brenner DJ. Estimating cancer risks from pediatric CT: going from the qualitative to the quantitative. Pediatr Radiol 2002; 32: 228-231.
  • 25. Gaillard EA, Carty H, Heaf D, Smyth RL. Reversible bronchial dilatation in children: comparison of serial high-resolution computer tomography scans of the lungs. Eur J Radiol 2003; 47: 215-220.
  • 26. Bastardo CM, Sonnappa S, Stanojevic S, et al. Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function. Thorax 2009; 64: 246-251.
  • 27. Haidopoulou K, Calder A, Jones A, et al. Bronchiectasis secondary to primary immunodeficiency in children: longitudinal changes in structure and function. Pediatr Pulmonol 2009; 44: 669-675.
  • 28. Shah NB, Platt SL. ALARA: is there a cause for alarm? Reducing radiation risks from computed tomography scanning in children. Curr Opin Pediatr 2008; 20: 243-247.
  • 29. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med 2007; 101: 1163-1170.
  • 30. Li AM, Sonnappa S, Lex C, et al. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? Eur Respir J 2005; 26: 8-14.
  • 31. Chan CH, Ho AK, Chan RC, et al. Mycobacteria as a cause of infective exacerbation in bronchiectasis. Postgrad Med J 1992; 68: 896-899.
  • 32. Hare KM, Grimwood K, Leach AJ, et al. Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian Indigenous children with bronchiectasis. J Pediatr 2010; 23 Jul [Epub ahead of print].
  • 33. King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007; 101: 1633-1638.
  • 34. Wickremasinghe M, Ozerovitch LJ, Davies G, et al. Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax 2005; 60: 1045-1051.
  • 35. Pizzutto SJ, Upham JW, Yerkovich ST, Chang AB. Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2010; (4): CD007525.
  • 36. Indinnimeo L, Tancredi G, Barreto M, et al. Effects of a program of hospital-supervised chest physical therapy on lung function tests in children with chronic respiratory disease: 1-year follow-up. Int J Immunopathol Pharmacol 2007; 20: 841-845.
  • 37. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009; 34: 1086-1092.
  • 38. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009; (1): CD000996.
  • 39. Chang CC, Singleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev 2009; (2): CD006316.
  • 40. Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009; 33: 312-318.
  • 41. Ellerman A, Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. Eur Respir J 1997; 10: 2376-2379.
  • 42. Fuschillo S, De FA, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008; 31: 396-406.
  • 43. Doucet-Populaire F, Buriankova K, Weiser J, Pernodet JL. Natural and acquired macrolide resistance in mycobacteria. Curr Drug Targets Infect Disord 2002; 2: 355-370.
  • 44. Dogru D, Nik-Ain A, Kiper N, et al. Bronchiectasis: the consequence of late diagnosis in chronic respiratory symptoms. J Trop Pediatr 2005; 51: 362-365.
  • 45. O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113: 1329-1334.
  • 46. Mutalithas K, Watkin G, Willig B, et al. Improvement in health status following bronchopulmonary hygiene physical therapy in patients with bronchiectasis. Respir Med 2008; 102: 1140-1144.
  • 47. Nici L, Raskin J, Rochester CL, et al. Pulmonary rehabilitation: what we know and what we need to know. J Cardiopulm Rehabil Prev 2009; 29: 141-151.
  • 48. Newall C, Stockley RA, Hill SL. Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax 2005; 60: 943-948.
  • 49. Katsura H, Ogata M, Kida K. Factors determining outcome in elderly patients with severe COPD on long-term domiciliary oxygen therapy. Monaldi Arch Chest Dis 2001; 56: 195-201.
  • 50. Oeseburg B, Wynia K, Middel B, Reijneveld SA. Effects of case management for frail older people or those with chronic illness: a systematic review. Nurs Res 2009; 58: 201-210.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.